How are MiMedx making their numbers?

"I don't know how they're hitting their numbers: that's what's blowing me away. What is going on? How are they supposedly hitting these numbers? I want to know." – Former MiMedx Employee

Viceroy continues piecing together further damning evidence of MiMedx's dwindling relationship with the Department of Veteran Affairs.

As a recap, we have established **flawed** and **dubious hiring practices** for MiMedx, **connections to related party** employee owned distributors, improper government filings, photographic evidence of channel stuffing and an undisclosed SEC investigation.

MiMedx refuse to acknowledge the facts. In what appears to be a blatant disregard for the SEC rules and the need for 8-K filing, MiMedx recently filed an 8-K for relating to a "Amendment to Credit Agreement", ignoring the elephant in the room: the SEC subpoena. According to MiMedx actions, an amendment to credit agreement" is significantly more important than the need to file an 8-K relating to an SEC subpoena. Viceroy believe that this is to avoid people tracking the issues of MiMedx and/or owning up to the seriousness of an on-going investigation.

This is in addition to MiMedx misleading its investors about the publication of an alleged independent report that was concealed from its own investors. As highlighted by Aurelius Value, MiMedx went one step further and prohibited its disclosure even when the SEC made enquiries². Investors would be prudent to check the SEC filings from April 18, 2017³

Viceroy's previous reports detailing fundamental issues within MiMedx (NASDAQ: MDXG) can be read here:

Part 1: https://viceroyresearch.org/2017/09/20/mimedxs-nasdaqmdxg-employment-of-kickback-bribery-scheme-inducers-makes-it-uninvestable/

Part 2: https://viceroyresearch.org/2017/09/26/the-same-old-story-mimedxs-response-is-typical-of-companies-trying-to-cover-their-tracks-and-is-unacceptable/

Part 3: https://viceroyresearch.org/2017/10/02/mimedxs-channel-stuffing-hard-evidence/

Part 4: https://viceroyresearch.org/2017/10/03/mimedxs-selective-non-compete-litigation-questionable-disclosures/

More to come...

¹ https://www.sec.gov/Archives/edgar/data/1376339/000137633917000124/mdxg2017102820178-klocdocu.htm

 $^{^{2}\,\}underline{\text{https://seekingalpha.com/article/4109861-mimedx-undisclosed-details-undermine-independent-investigation}}$

³ https://www.sec.gov/Archives/edgar/data/1376339/000137633917000066/filename1.htm

Important Disclaimer - Please read before continuing

This report has been prepared for educational purposes only and expresses our opinions. This report and any statements made in connection with it are the authors' opinions, which have been based upon publicly available facts, field research, information, and analysis through our due diligence process, and are not statements of fact. All expressions of opinion are subject to change without notice, and we do not undertake to update or supplement any reports or any of the information, analysis and opinion contained in them. We believe that the publication of our opinions about public companies that we research is in the public interest. We are entitled to our opinions and to the right to express such opinions in a public forum. You can access any information or evidence cited in this report or that we relied on to write this report from information in the public domain.

To the best of our ability and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and who are not insiders or connected persons of the stock covered herein or who may otherwise owe any fiduciary duty or duty of confidentiality to the issuer. We have a good-faith belief in everything we write; however, all such information is presented "as is," without warranty of any kind – whether express or implied.

In no event will we be liable for any direct or indirect trading losses caused by any information available on this report. Think critically about our opinions and do your own research and analysis before making any investment decisions. We are not registered as an investment advisor in any jurisdiction. By downloading, reading or otherwise using this report, you agree to do your own research and due diligence before making any investment decision with respect to securities discussed herein, and by doing so, you represent to us that you have sufficient investment sophistication to critically assess the information, analysis and opinions in this report. You should seek the advice of a security professional regarding your stock transactions.

This document or any information herein should not be interpreted as an offer, a solicitation of an offer, invitation, marketing of services or products, advertisement, inducement, or representation of any kind, nor as investment advice or a recommendation to buy or sell any investment products or to make any type of investment, or as an opinion on the merits or otherwise of any particular investment or investment strategy.

Any examples or interpretations of investments and investment strategies or trade ideas are intended for illustrative and educational purposes only and are not indicative of the historical or future performance or the chances of success of any particular investment and/or strategy.

As of the publication date of this report, you should assume that the authors have a direct or indirect interest/position in all stocks (and/or options, swaps, and other derivative securities related to the stock) and bonds covered herein, and therefore stand to realize monetary gains in the event that the price of either declines.

The authors may continue transacting directly and/or indirectly in the securities of issuers covered on this report for an indefinite period and may be long, short, or neutral at any time hereafter regardless of their initial recommendation.

We call on MiMedx to immediately disclose how many VA Facilities they have been barred, suspended or banned from doing business with

Previously we identified corroborating <u>photographic</u> evidence to channel stuffing allegations within Whistleblower court proceedings. Having interviewed a whistleblower **not connected with any legal proceedings,** Viceroy now call upon MiMedx to update its investors immaterially on the following:

How many Veteran Affairs facilities have MiMedx been barred, suspended, or banned from doing business with?

Note:

Although MiMedx triumphed in their settlement with Hal Purdy, we still believe there is still cause for concern regarding statements in part of the case. We question how the loss of Hal Purdy's clients and sales did not have a material impact on revenue.

As a reminder to readers, it was highlighted in MiMedx Inc Vs Hal Purdy & Recon Medical Devices LLC -CAUSE NO. DC-16-16478

particular tactic on December 15 and 16, 2016, the South Texas Veteran's Health Care System in San Antonio, Texas no longer allowed representatives selling products to market their products to podiatry in the facility, which ultimately went hospital wide and is still enforced today. This is evidenced by an email exchange between RK Simon and Kevin Lilly which discusses being shut out of the facility on December 21, 2016. As a result, Purdy lost the ability to perform his job with respect to roughly ninety-seven percent of his volume. The channel stuffing actions and

Figure 1 Extract from CAUSE NO. DC-16-16478

Why did MiMedx not notify its investors that was shut out of such a significant facility in terms of sales?

Since Viceroy has started investigating MiMedx's relationship with the VA, we have been in communication with whistleblowers whose evidence has been provided to the SEC & VA OIG.

We believe MiMedx's revenues were materially impaired by their channel stuffing conduct and they have failed to notify the market of material changes in the business.

Whistleblower 11 is a former employee with no legal proceedings pending or implied against MiMedx who had material concerns of such severity regarding MiMedx's business practices that they reached out to us. They have a proverbial "goody-bag" of evidence regarding MiMedx's channel stuffing which has been forwarded to the SEC.

Investors would be wise to question why MiMedx did not alert them as to their loss of significant business due to their channel stuffing activities. Investors should take note that we will be presenting a full dossier on MiMedx's conduct and strained relations with the VA very shortly. The facts in this article in particular are

especially significant, something MiMedx will realize in time when various FOIA and related public access requests to certain bodies are brought to light.

Below is an extract from a transcript of Viceroy's communication with Whistleblower 11 – we believe investors should be concerned:

WHISTLEBLOWER 11 [Edited to remove possible identifying comments]...[MiMedx] shot themselves in the

foot because they've lost all that business. I don't think they've gotten it back. I don't know how they're hitting their numbers that's what's blowing me away. What is going on? How are they supposedly hitting these numbers? I want to know.

INTERVIEWER Well apparently the market believes them. Yeah

WHISTLEBLOWER 11 Well yeah, because they..., most of these big VA's they've been kicked out of so I

don't know...I don't know.

INTERVIEWER Oh wow,

WHISTLEBLOWER 11 I don't know, this is crazy.

INTERVIEWER So, you know where they've been kicked out of the big VA's? Is there-

WHISTLEBLOWER 11 Atlanta VA would be a big one.

INTERVIEWER Yeah?

WHISTLEBLOWER 11 And numerous ones around the country-

- Break - Other conversation

INTERVIEWER Yeah so, the Atlanta VA right so why were they kicked out of there?

WHISTLEBLOWER 11 Well uh they were channel stuffing I believe number one and uh number two they

were using a ridiculous- they were using and reselling a lot of product through one doctor there. And they eventually just shut him down because I think he was abusing it. He was a speaker for- for us Frenchman is his last name. I think its Jeff Frenchman and we were doing hundreds of thousands probably a month with him.

And um

INTERVIEWER Wow

WHISTLEBLOWER 11 There may have been some illegal activity but I don't know what

Jeffrey Frenchman DPM

Viceroy's research confirms that the "Jeff Frenchman" mentioned in the transcript above is Jeffrey Frenchman. Initial checks show that Jeffrey Frenchman does indeed work for the VA confirmed in an excerpt from the Atlanta VA website below:

Atlanta VA Medical Center

The Veterans Health Administration wants to provide helpful information to our Veterans and their caregivers. The last regular update to the information on this website was April 2015. For current information on <u>physicians</u>, we encourage you to use the "Docinfo" service offered by the Federation of State Medical Board (FSMB) at http://www.docinfo.org (http://www.docinfo.org). The FSMB website is updated monthly and is a public website to provide information related to any physician who is licensed in any US state, territory, or district.

We look forward to sharing a new website in the near future that we are developing which will be easier for you to use with current information. Please be aware that practitioners' current license(s) and board certification(s) are time-limited and may have changed since the last regular update in April 2015. If you have a concern about a provider to whom you have been referred, please speak with your health care team. If you have a question about care you have already received, please contact the Patient Advocate at your facility.

Jeffrey Frenchman, DPM

Figure 2 Veterans Health Administration⁴

Jeffrey Frenchman is also connected with MiMedx, as per MiMedx's own press release from October 2016 5.

MiMedx will sponsor a Breakfast Symposium entitled "Addressing Complex and Chronic Wounds with EpiFix dehydrated Human Amnion/Chorion Membrane (dHACM) Allografts and New Amniotic Products" on Friday, October 7th from 7:30am to 9:00am in the Milani III and IV Ballroom. The list of faculty and their respective topics presented during the breakfast symposium include: Deffrey Frenchman, DPM, presenting an introduction to EpiFix, clinical data overview and case examples. James Stavosky, DPM, imparting his experience with MiMedx products in podiatric applications; Susan Hagen, MD, discussing complex wound healing and treatment with MiMedx products; and Michele Massee, Manager of Biomedical Research at MiMedx, providing an overview of published scientific data with key focus on diabetic patients' cellular proliferation experience.

Figure 3 MiMedx Press Release October 2016

Not only is Jeffrey Frenchman a keynote speaker at MiMedx events, but he is practicing out of a VA facility in Atlanta, Georgia; a fact corroborated by Viceroy's communication with former MiMedx employees. These same employees have also provided records and information regarding MiMedx's channel stuffing activities.

We note within the court filings between MiMedx and Hal Purdy regarding his breach of his Non-Compete agreement: it is stated that MiMedx was prevented from doing business at VA's whilst allegations were being investigated about channel stuffing.

Based on the information provided to Viceroy by Whistleblower 11 regarding MiMedx's conduct at VA facilities in Atlanta we are filing an additional submission with the SEC and Office of the Inspector General for the Veterans Administration.

Conclusion

As more facts come to light we urge MiMedx investors to seriously question management's selective disclosures.

In spite of many former MiMedx employees coming forward to provide information, thus corroborating extensive investigations conducted by Viceroy and Aurelius Value, MiMedx seems to be keeping investors misinformed and in the dark.

⁴ https://www.va.gov/providerinfo/atlanta/detail.asp?providerid=749

 $[\]frac{5}{http://www.prnewswire.com/news-releases/advances-in-regenerative-medicine-with-mimedx-epifix-and-amniofix-to-be-presented-at-sawc-fall-meeting-300340407.html}\\$